2023
Association Between Hospital-Documented Atrial Fibrillation and Central Retinal Artery Occlusion
Lusk J, Song A, Unnithan S, Al-Khalidi H, Delic A, de Havenon A, Biousse V, Schrag M, Poli S, Piccini J, Xian Y, O’Brien E, Mac Grory B. Association Between Hospital-Documented Atrial Fibrillation and Central Retinal Artery Occlusion. Stroke 2023, 54: 983-991. PMID: 36729390, PMCID: PMC11173326, DOI: 10.1161/strokeaha.122.042292.Peer-Reviewed Original ResearchConceptsCentral retinal artery occlusionRetinal artery occlusionCardiovascular comorbiditiesArtery occlusionAtrial fibrillationInverse associationNon-Hispanic white race/ethnicityState Emergency Department DatabasesWhite race/ethnicityPrespecified sensitivity analysisPrimary end pointRisk of strokeCause-specific hazards modelEmergency Department DatabasesEmergency department settingPrimary risk factorState Inpatient DatabasesPositive control outcomesRace/ethnicityMedian followCohort studyCumulative incidenceIschemic strokeAF statusInpatient Database
2022
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnel
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply